The cardiovascular, coagulation and haematological effects of Tiger Snake (Notechis scutatus) venom were investigated in anaesthetized, mechanically ventilated dogs. Intravenous infusion of venom caused dose-related systemic hypotension, low cardiac output, pulmonary hypertension and raised pulmonary artery occlusion pressure. These effects occurred within several minutes of venom administration but recovered over 30 to 40 minutes. They were accompanied by prolongation of prothrombin and activated partial thromboplastin times and by depletion of serum fibrinogen. Fibrin degradation products were not detected. Thrombocytopenia and leucopenia were observed within minutes of venom administration but recovered over 30 to 40 minutes. The mechanism of systemic hypotension is probably pulmonary vascular obstruction and coronary ischaemia caused by disseminated intravascular coagulation, although the existence of a myocardial depressant in venom or release of vasoactive substances by venom cannot be excluded.
SutherlandS.K.Australian Animal Toxins: The Creatures, their Toxins and Care of the Poisoned Patient.Oxford University Press, Melbourne1983.
2.
SutherlandS.K.Deaths from snake bite in Australia, 1981–1991.Med J Aust1992; 157: 740–746.
3.
SutherlandS.K., LeonardR.L.Snakebite deaths in Australia 1992–1994 and a management update.Med J Aust1995; 163: 616–618.
4.
MartinC.J.On some effects upon the blood produced by the injection of the venom of the Australian Black Snake (Pseudechis porphyriacus).J Physiol1894; XV: 380–401.
5.
FeldbergW., KellawayC.H.The circulatory and pulmonary effects of the venom of the Australian Copperhead (Denisonia superba).Aust J Exp Biol Med Sci1937; 15: 81–95.
6.
TibballsJ., SutherlandS., KerrS.Studies on Australian snake venoms. Part 1: The haemodynamic effects of Brown Snake (Pseudonaja) species in the dog.Anaesth Intensive Care1989; 17: 466–469.
7.
BroadA.J., SutherlandS.K., CoulterA.R.The lethality in mice of dangerous Australian and other snake venoms.Toxicon1979; 17: 664–667.
8.
AltmanD.G.Practical statistics for medical research.Chapman & Hall, London; 1991.
9.
MorrisonJ.J., PcarnJ.H., CoulterA.R., TannerC., CharlesN.T.The quantity of venom injected by clapid snakes.Toxicon1983: suppl 3: 309–312.
10.
LeeC.Y.Chemistry and pharmacology of polypeptide toxins in snake venoms.Ann Rev Pharmacol1972; 12: 265–286.
11.
LeeC.Y., LeeS.Y.Cardiovascular effects of snake venoms. In: LeeC.Y. ed. Snake Venoms, Handbook of Experimental Pharmacology, vol 52, Springer-Verlag, Berlin1979; 547–590.
12.
KellawayC.H., LeMessurierD.H.The vaso-depressant action of the venom of the Australian Copperhead (Denisonia superba).Aust J Exp Biol Med Sci1936; 14: 57–76.
13.
FeldbergW., KellawayC.H.Circulatory effects of the venom of the Indian Cobra (Naia naia) in cats.Aust J Exp Biol Med Sci1937; 15: 159–172.
14.
FeldbergW., KellawayC.H.Circulatory effects of the venom of the Indian Cobra (Naia naia) in dogs.Aust J Exp Biol Med Sci1937; 15: 441–460.
15.
BhanganadaK., PerryJ.F.Cardiovascular effects of Cobra venom.JAMA1963; 183: 257–259.
16.
FrancisB., JohnT.R., SeebartC., KaiserH.New toxins from the venom of the common Tiger Snake (Notechis scutatus scutatus).Toxicon1991; 29: 85–96.
17.
FairleyN.H.Criteria for determining the efficacy of ligature in snake bite.Med J Aust1929; 1: 377–394.
18.
TibballsJ.Cardiovascular, coagulation and haematological effects of Brown and Tiger snake venoms. MD Thesis. The University of Melbourne, 1998.
19.
FryB.G.Structure-function properties of venom components from Australian elapids.Centre for Drug Design and Development, University of Queensland, St Lucia, Old (undated).
20.
FrancisB., CoffieldJ.A., SimpsonL.L., KaiserH.Amino acid sequence of a new type of toxic phospholipase A2 from the venom of the Australian Tiger Snake (Notechis scutatus scutatus).Arch Biochem Biophys1995; 318: 481–488.
21.
BarnesP.J., HensonP.M.Platelet-activating factor. In: CrystalR.G., WestJ.B., BarnesPJ., ChcrniackN.S., WebelE.R., eds. The Lung, Scientific Foundations.Raven Press Ltd, New York1991; 49–59.
22.
CamussiG., AgliettaM., MalavasiF.The release of platelet-activating factor from human endothelial cells in culture.J Immunol1983; 131: 2397–2403.
23.
ChignardM., LeCouedicJ.P., VargaftigB.B., BenvenisteJ.Platelet-activating factor (PAF-acether) secretion from platelets; effect of aggregating agents.Br J Haematol1980; 46: 455–464.
24.
OgletreeM.L.Overview of physiological and pathophysiological effects of thromboxane A2. A review.Fed Proc1987; 46: 133–138.
25.
PiperP.J., StewartA.G.Antagonism of vasoconstriction induced by platelet-activating factor in guinea-pig perfused hearts by selective platelet-activating factor receptor antagonists.Br J Pharmacol1987; 90: 771–783.
26.
TansG., Govers-ReimslagJ.W.P., van RijnJLML, RosingJ.Purification and properties of a prothrombin activator from the venom of Notechis scutatus scutatus.J Biol Chem1985; 260: 9366–9370.
27.
MarshallL.R., HerrmannR.P.Coagulant and anticoagulant actions of Australian snake venoms.Thrombos Haemostas1983; 50: 707–711.
28.
MarshallL.R., HerrmannR.P.Australian snake venoms and their in vitro effect on human platelets.Thrombos Res1989; 54: 269–275.
29.
LewisP.F.Some toxicity thresholds for the clinical effects of common tiger snake (Notechis scutatus) envenomation in the dog.Aust Vet J1994; 71: 133–135.
